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Fatigue in patients with inactive sarcoidosis does not correlate 
with lung ventilation ability or walking distance. Pilot Study
Zmęczenie u chorych z nieaktywną sarkoidozą nie koreluje ze zdolnością 
wentylacyjną płuc oraz z dystansem chodu. Badanie pilotażowe
The work has been conducted under a grant from the Silesian Medical University: project No. KNW-1-025/D/2/0
Abstract
Introduction: Fatigue is one of many symptoms reported by patients with sarcoidosis. It is believed that fatigue may be the 
cause of exercise intolerance and reduced quality of life in patients with sarcoidosis. The purpose of the work was to present the 
frequency of fatigue prevalence in patients with sarcoidosis and to investigate the correlation between fatigue and the results of 
pulmonary function tests and walking distance.
Material and methods: A total of 74 patients with sarcoidosis in a stable phase of the disease, not treated in the past with 
glucocorticoids or immunosuppressive drugs, and without indications for treatment at the time of the study were examined. In 
all patients fatigue evaluation was carried out with the use of the Fatigue Assessment Scale questionnaire (FAS); dyspnoea was 
assessed with the use of the Medical Research Council scale (MRC). Body Mass Index (BMI), spirometry, and a 6-minute walk 
test were additionally performed. The control group included 30 healthy volunteers who completed the FAS.
Results: In the examined group of patients fatigue was diagnosed in 36 patients (50%), and in 5 (6.94%) - strong fatigue was 
observed. The remaining 31 (43.06%) patients felt no fatigue. The average value of points obtained by FAS questionnaire in sar-
coidosis patients was significantly higher than the respective value in the control group (p = 0.02). A significantly higher number 
of points by FAS questionnaire was observed in female patients with sarcoidosis (p = 0.04) in comparison to men. No significant 
statistical correlation between fatigue index FAS and BMI (r = 0.22, p = 0.11), FEV1 (r = –0.11, p = 0.3), FEV1% pred. (r = 
0.01, p = 0.9), FVC (r = −0.03, p = 0.77), FEF25−75 (r = −0.23, p = 0.1) and the distance in the six-minute walk test (6MWT) 
(r = −0.01, p = 0.9) was observed. However, there was a weak negative correlation between the age of the patients and the 
FAS index (r = −0.29, p = 0.01).
Conclusions: Fatigue in patients with sarcoidosis does not correlate with the results of lung function tests or with walking 
distance in 6MWT. 
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Streszczenie
Wstęp: Zmęczenie jest jednym z wielu zgłaszanych objawów u chorych na sarkoidozę. Uważa się, że zmęczenie może być 
przyczyną nietolerancji wysiłku fizycznego u chorych na sarkoidozę oraz obniżenia jakości życia. Celem pracy jest przedstawienie 
częstości występowania zmęczenia u chorych na sarkoidozę oraz zbadanie korelacji pomiędzy zmęczeniem a wynikami badań 
czynnościowych płuc i dystansem chodu.
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Materiał i metody: Zbadano 74 chorych na sarkoidozę w stabilnym okresie choroby, nieleczonych w przeszłości glikokortykoidami 
lub lekami immunosupresyjnymi i bez wskazań do leczenia w chwili badania. U wszystkich chorych dokonano oceny zmęczenia 
kwestionariuszem FAS (Fatigue Assesment Scale), oceniono duszność za pomocą skali MRC (Medical Research Council). Zbadano 
również wskaźnik masy ciała BMI (body mass index) oraz dokonano oceny spirometrycznej oraz przeprowadzono 6-minutowy test 
chodu. Badaniem objęto również 30 zdrowych ochotników, u których dokonano oceny zmęczenia (FAS).
Wyniki: W badanej grupie chorych stwierdzono zmęczenie u 36 (50%), a u 5 (6,94%) bardzo duże zmęczenie. Pozostałych 31 
(43,06%) pacjentów nie odczuwało zmęczenia. Średnia wartość uzyskanych punktów wg kwestionariusza FAS u chorych na sa-
koidozę była istotnie wyższa niż obserwowana wartość w grupie kontrolnej (p = 0,02) . Istotnie większą liczbę punktów według 
kwestionariusz FAS obserwowano u kobiet chorych na sarkoidozę (p = 0,04) w porównaniu z mężczyznami. Nie stwierdzono 
istotnych statystycznie zależności pomiędzy wskaźnikiem zmęczenia FAS a BMI (r = 0,22, p = 0,11), FEV1 (r = −0,11 p = 0,3), 
FEV1% pred. (r = 0,01, p = 0,9), FVC (r = −0,03, p = 0,77), FEF25−75 (r = −0,23, p = 0,1) oraz dystansem w teście sześcio-
minutowego marszu (r = −0,01, p = 0,9). Stwierdzono natomiast słabą ujemną korelację między pomiędzy wiekiem badanych 
chorych a wskaźnikiem FAS (r = −0,29, p = 0,01).
Wnioski: Zmęczenie u chorych na sarkoidozę nie wpływa na dystans chodu i na zdolność wentylacyjną płuc.
Słowa kluczowe: zmęczenie, sarkoidoza, testy czynnościowe płuc, 6-minutowy test marszu
Pneumonol. Alergol. Pol. 2015; 83: 15–22
Introduction
Sarcoidosis is a multiorgan disorder that is 
characterised by the formation of noncaseating 
granulomas in many different organs. The disease 
often (in 80−90% of patients) involves the lungs 
and lymph nodes located in the chest [1, 2]. It 
affects mainly young people between 25 and 35 
years of age [1]. 
Clinical signs of sarcoidosis are generally 
nonspecific. The most frequent complaints re-
ported by Caucasian patients, include: dyspnoea 
(approximately 50% of patients), exercise into-
lerance (58% of patients), muscular pain (29%), 
and ocular problems (about 25%) [1, 2]. Fever as 
a nonspecific sign is observed in as many as 32% 
of patients [3]. 
Cough, muscular, chest and joint pains, or 
weight loss are non-specific signs, which may 
be present also in other systemic or neoplastic 
diseases [4, 5]. Clinical signs of the disease and 
the number of extrathoracic organs involved differ 
significantly between Caucasian, Afro-American, 
or Asian patients [5]. 
According to many authors, one of the symp-
toms most frequently reported by patients with sar-
coidosis but underrated by doctors, is fatigue, which 
may occur even in 30 to 90% of patients [4, 6, 7]. 
Fatigue is a subjective symptom reported 
not only by patients with sarcoidosis but also by 
patients with neoplastic, infectious, and rheuma-
tologic diseases [2, 8]. It is described as a sensa-
tion of overwhelming strength reduction, lack of 
energy and the feeling of complete exhaustion [2, 
9, 10]. It may be experienced at rest and it usually 
increases under stress over the course of the day. 
Fatigue frequently coexists with depression, from 
which it differs in the lack of lowered self-eva-
luation, despair, and the sense of hopelessness 
[2, 9, 10].
Fatigue may substantially influence everyday 
functioning of patients, inter alia, their occupa-
tional and social life or physical activity [2]. 
It is believed that fatigue and general strength 
reduction of the organism may cause exercise 
intolerance and lower the quality of life in sar-
coidosis patients [8, 11]. The majority of patients 
complain of concomitant fatigability of the lower 
extremities [8]. 
The aim of the study was to present the 
prevalence of fatigue in patients with stable sar-
coidosis not treated with glucocorticoids, and to 
investigate correlation between fatigue and lung 
function test results and exercise capacity.
In Poland, research into the occurrence of 
fatigue in patients with sarcoidosis has not been 
carried out to date; neither has the influence of 
fatigue on exercise tolerance and patients’ activity 
has been defined. 
Material and methods
The study included 74 patients with sar-
coidosis (21 women and 53 men) aged 29−71 
years (the mean age 45.3 years), who reported 
to the Outpatient Clinic of the Hospital for Lung 
Diseases and Tuberculosis in Zabrze in the pe-
riod from 01.06.2008 to 01.08.2008 and from 
01.01.2010 to 01.03.2010. None of the women par-
ticipating in the research was pregnant at the time 
of the study. Sarcoidosis was diagnosed earlier at 
the Teaching Hospital of Lung Diseases and Tuber-
culosis in Zabrze in accordance with the criteria 
of the American Thoracic Society/World Asso-
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Table 1. General characteristics of treated and control group
Treated group Control group
Total (n) 74 30
Women (n) 21 15
Men (n) 53 15
Age (yrs) 43.5 (29−71) 49.7 (29−68)
Stage of sarcoidosis:
I
II
III
21
23
24
BMI (kg/m²) 26.6 25.2
FAS (ponts) mean/SD 22.9 ± 7.3 SD 18.1 ± 4.3 SD
FEV (1) mean/SD 3.18 ± 0.82 SD
FEV1 % pred. mean/SD 90.4 ± 13.1 SD
FVC (l) mean/SD 4.16 ± 1.1 SD
FVC % pred. mean/SD 98.9 ± 13.9 SD
FEV1/FVC(%) mean/SD 95 ± 9.6 SD
FEF 25−75 (l/s) mean/SD 3.7 ± 1.2 SD
FEF25−75 % pred. mean/SD 89.4 ± 26.5 SD
6MWT (m) mean/SD 555.9 ± 91.5 SD
MRC (ponts) mean/SD 1.21 ± 0.8 SD
All abbreviations in the text
ciation for Sarcoidosis and Other Granulomatous 
Disorders (ATS/WASOG) [1]. The study group 
consisted of 21 patients at radiological stage I, 
23 at stage II, and 24 at stage III of sarcoidosis. 
None of the patients smoked cigarettes. According 
to the available documentation, the duration 
of sarcoidosis did not exceed four years. Only 
the patients at a stable stage of the disease, not 
treated in the past with glucocorticoids or immu-
nosuppressive drugs, and with no indications for 
treatment according to the ATS/WASOG criteria 
during the examination, entered the study. No 
symptoms of extrapulmonary sarcoidosis or other 
chronic concomitant disorders or signs of acute 
infection were observed in the patients during the 
period of at least three months prior to the study.
In all patients, dyspnoea was evaluated using 
the MRC scale [12], and fatigue — with the help of 
the Polish version of the Fatigue Assessment Scale 
(FAS), calculating the so-called “FAS index” [6]. 
The authors of the FAS gave their consent for use 
of the scale in the present study.
We measured fatigue with the help of the FAS 
questionnaire, which is used more often and is 
more objective than other questionnaires, such as: 
the Energy and Fatigue Scale of the World Health 
Organization Quality of Life Assessment Instru-
ment — 100 (WHOQOL-100), Fatigue Scale (FS), 
and Functional Assessment of Chronic Illness 
Therapy — Fatigue (FACIT-F) [15].
The FAS questionnaire includes 10 questions 
concerning the frequency of physical and mental 
fatigue during the previous year (Table 1). There 
are five possible answers to the questions: “never, 
sometimes, regularly, often, and always”, which 
are evaluated on a scale from 1 to 5.
The results of the FAS were classified as: no 
fatigue (10−21 points), fatigue (22−34 points), 
and very strong fatigue (35−50 points) [6].
In all of the patients from the present study, 
BMI was calculated and spirometry was per-
formed, using Lungtest apparatus produced by 
MES (MES-SC Kraków Poland), in accordance 
with the ATS/ERS guidelines and Polish guide-
lines for spirometry [PTCHP (Polish Society of 
Lung Diseases) 2006 [13]. The obtained results 
of forced vital capacity (FVC), forced expiratory 
volume in 1 second (FEV1), and forced expirato-
ry flow (FEF25−75) were expressed as a percentage 
of predicted values according to Quanjer et 
al. [14]. Additionally, in accordance with the 
guidelines of the American Thoracic Society 
of 2002 [15], a 6-minute walk test (6MWT) was 
performed.
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Table 2. Fatigue Assesment Scale
Never Sometimes Regular Often Always
1. I am bothered by fatigue 1 2 3 4 5
2. I get tired very quickly 1 2 3 4 5
3. I don’t do much during the day 1 2 3 4 5
4. I have enough energy for everyday life 1 2 3 4 5
5. Physically, I feel exhausted 1 2 3 4 5
6. I have problems to start things 1 2 3 4 5
7. I have problems to think clearly 1 2 3 4 5
8. I feel no desire to do anything 1 2 3 4 5
9. Mentally, I feel exhausted 1 2 3 4 5
10. When I am doing something, i can concentrate quite well 1 2 3 4 5
Fatigue was also measured using the FAS 
questionnaire in a control group of 30 healthy 
volunteers. The control group consisted of 15 men 
and 15 women. No one from the control group 
reported any concomitant diseases. The group 
of healthy volunteers did not undergo any other 
diagnostic tests. 
The study was approved by the Bioethics 
Committee of the Medical University of Silesia.
Statistical evaluation of the obtained results, 
after examining normal distribution, was con-
ducted using one-way analysis of variance, the 
Kruskal-Wallis test, and non-parametric Wilcoxon 
test. The relation between the variables was eva-
luated using Pearson and Spearman correlation 
analysis. Multiple regression analysis was also 
applied. P < 0.05 was assumed as statistically 
significant. 
Results
Demographic data and mean values of the 
results obtained in the FAS and function tests 
outcome are presented in Table 2. 
According to the FAS, 36 (50%) sarcoidosis 
patients felt fatigue, and 5 (6.94%) — strong 
fatigue. The remaining 31 (43.06%) patients 
did not feel fatigue. In the control group, 
7 (23.33%) healthy individuals reported fatigue, 
and the remaining 21 (76.67%) were free from 
this symptom. 
The mean FAS score in patients with sarcoido-
sis was significantly higher than the FAS score in 
the control group (p = 0.02). FAS score was signi-
ficantly higher in females than in males (p = 0.04) 
(Fig. 1). The mean number of points obtained 
from the FAS was not significantly different in 
patients at stage I, II, or III of sarcoidosis (Fig. 2). 
No statistically significant correlations were fo-
und between the FAS index and BMI.
There was no significant correlation between 
the FAS index and lung function tests results (Figs 
3−5). They were: for FEF25−75 (r = 0.23, p = 0.1), 
for FEV1 (r = 0.05, p = 0.96), and for FVC (r = 
0.03, p = 0.77), 
No correlation between 6-minute walking 
distance and FAS score was found either (r = 
0.01, p = 0.9) (Fig. 6). 
However, a weak negative correlation be-
tween the age of the examined patients and the 
FAS index was found (r = −0.29, p = 0.02) (Fig. 7). 
In the group of healthy subjects, no statistically 
significant differences were found between the 
age of the examined individuals and the FAS 
index (r = 0.3, p = 0.09) 
Discussion
No correlation between fatigue and lung 
ventilation ability or exercise tolerance measu-
red with a 6-minute walk test was found in the 
examined patients, which suggests that fatigue 
does not have an impact on exercise tolerance. 
Using the FAS questionnaire in the selec-
ted group of ambulatory patients with chronic, 
stable sarcoidosis in remission, we observed 
fatigue in 56.94% of the subjects. The study was 
not epidemiological, and it included a small 
number of selected patients with no indication 
for treatment. Hence, the obtained data cannot 
be compared with the results produced by other 
authors, whose studies were conducted on con-
siderably greater groups of patients making up 
a complete clinical cross-section. According to 
data collected in Denmark, fatigue measured with 
the FAS was reported by as many as 71% out of 
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Figure 1. Comparison of the fatigue indicator FAS with gender
Figure 2. Comparison of the fatigue indicator FAS with disease stage
1,755 interviewed individuals [16, 17]. Fatigue 
was the most frequent symptom reported by 
patients with sarcoidosis of different degrees of 
activity [3]. Research carried out in Germany on 
1,197 patients showed that nearly 62% of men 
and 74% of women complained of fatigue [18]. 
Korenromp et al. in the Netherlands examined 
75 patients with sarcoidosis, and 76% of them 
reported fatigue in the course of the disease. Yet, 
the patients were not examined with the help of 
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Figure 3. Correlation between the fatigue indicator FAS and the forced 
expiratory flow (FEF25−75)
Figure 4. Correlation between the fatigue indicator FAS and forced 
expiratory volume in 1 second (FEV1)
Figure 5. Correlation between the fatigue indicator FAS and the forced 
vital capacity (FVC)
Figure 6. Correlation between the fatigue indicator FAS and the distan-
ce in 6-minute walk test
the FAS questionnaire but with the Checklist In-
dividual Strength (CIS), Medical Outcomes Study 
36-Item Short-Form Health Survey (SF-36), and 
Symptom Checklist-90 (SCL-90) [19].
Among our patients, women also had a higher 
FAS index than men did, whereas BMI did not 
correlate with degree of fatigue measured with 
the FAS. Other authors indicated higher values 
of the FAS index in older patients, i.e. at the age 
of 51−60 years, which was confirmed by us in 
the present study. 
In sarcoidosis, fatigue may be intensified by 
acute stage of the disease, obesity, or glucocorti-
coid use [20]. Sleep apnoea may also have some 
influence on fatigue sensation. Other possible 
causes of fatigue in sarcoidosis include the fol-
lowing: inflammatory process with formation of 
sarcoidal granulomas, myopathy, concomitant 
chronic pain disorders, feeling of general strength 
reduction, depression, and small fibre neuropathy 
(SFN) [21]. However, the causes of fatigue in sar-
coidosis have not been clearly determined [6, 9].
The research by Alhamad, Baughman, and 
Spruit [22, 23] showed that 73% of sarcoidosis 
patients in 6MWT covered a distance shorter 
than 400 m, and their exercise tolerance measu-
red with this test is markedly lower than that of 
healthy individuals [22]. In the research by Mil-
ler [18, 24], 67% of patients stopped during the 
test due to “weakness of the lower extremities”, 
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In Germany Kabitz conducted a 6-minute 
walk test on a small group of 24 sarcoidosis male 
patients. In comparison with the control group, 
the subjects covered significantly shorter distance 
p = 0.025, but fatigue was not evaluated by any 
questionnaire [30].
In our group of patients, there were no indivi-
duals with radiological or functional progression, 
which markedly intensifies the sensation of fati-
gue [3]. However, we did not analyse the impact 
of social factors such as education or profession 
on fatigue sensation. According to some authors, 
active professional work and regular physical 
exercise decrease depression, strength reduction, 
and the feeling of fatigue in chronic diseases of 
the respiratory system [8]. 
Conclusions
In the study group, no correlation was fo-
und between fatigue and walking distance or 
lung ventilation ability. The cause of fatigue 
in patients with sarcoidosis remains unknown 
and the problem undoubtedly needs further 
research.
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